Capital will not be an issue for SLS with sale of Suven Pharma.
Some of the molecules looks to be near completion.
I owned before demerger and exited only SLS post demerger. Hold on to Pharma.
Advent To Buy Suven Pharma In A Rs 9,589-Crore Deal | BQ Prime
Disc: Now invested again in SLS with small quantity to track.
| Subscribe To Our Free Newsletter |
